TG Therapeutics Inc (TGTX)

Price $54.17 · +1.90% today · $8.3B market cap.

biotech_pharma

Strongest Overalllow risk← Back

Simulated history. Equities don't yet have ingested OHLCV, so the price chart and technical indicators below are illustrative (deterministic, labelled) — not real market history.

Price & Performance

$54.17 -2.0% over 1Y

Simulated history — illustrative, not real market data.

Today

+1.90%

1 week

+1.63%

1 month

-2.89%

1 year

+61.75%

Technical Analysis

RSI (14)

42.70

MACD

-1.68

MACD signal

-1.52

MACD hist

-0.16

SMA 20

56.30

SMA 50

58.55

EMA 20

55.35

ATR (14)

1.69

Support

51.18

Resistance

63.12

Bollinger upper

62.77

Bollinger lower

49.82

▹ RSI 43 — neutral
▹ MACD below signal (bearish)
▹ Price below moving averages

Indicators describe past price action — they do not predict future direction.

Fundamental Analysis

P/E ratio

18.78

Return on equity

72.30%

EBITDA

n/a

EPS (TTM)

2.75

Net debt

n/a

Net margin

55.22%

Gross margin

82.37%

Current ratio

4.27

Debt / Equity

1.23

Dividend yield

n/a

Operating margin

15.91%

Revenue growth (YoY)

76.08%

Risk Assessment

Ann. volatility

27.7%

Max drawdown

20.1%

Liquidity

Adequate market capitalization

Leverage

Debt/equity 1.2 (manageable)

Valuation

P/E 19×

Earnings

Earnings dates are not tracked in this release.

Concentration

Single-name equity — no diversification within the position.

Estimated annualized volatility 28% with a maximum drawdown of 20% over the available window.

Investment Thesis (generated summary)

TG Therapeutics Inc (TGTX) screens constructively on the current data, with an opportunity score of 72/100. The score reflects the available fundamental, technical, valuation and sentiment inputs — it is a research screen, not a forecast or a recommendation to trade.

Bullish case

Strong net margin (55%)
Revenue growing 76% y/y
Reasonable P/E (19×)

Potential catalysts

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
Apple, Salesforce Lead Five Stocks Near Buy Points
Meta, Tesla, SpaceX Take Center Stage As Earnings Season Kicks Into High Gear. Everything You Need To Know.

Horizon: ~1–3 months for technical signals; 12+ months for fundamental quality.

Thesis invalidated if: Momentum reverses and price breaks below its 50-day average; Earnings or guidance disappoint relative to consensus; A sector-level drawdown outweighs stock-specific strength.

News Sentiment

Bullish 12.5%Neutral 87.5%Bearish 0%